NIPH Clinical Trials Search

UMIN ID: UMIN000001098

Registered date:26/03/2008

Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedNon-small cell lung cancer
Date of first enrollment2007/05/01
Target sample size100
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Docetaxel plus zoledronic acid Docetaxel


Primary OutcomeProgression free survival
Secondary OutcomeSafety, Response rate, SRE rate, SRE free survival, Over all survival

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria>Previous treatment with docetaxel or zoledronic acid >Regular use of corticosteroidOral complication

Related Information


public contact
Name Shinichiro Nakamura
Address Japan
Telephone 06-6633-7400
Affiliation West Japan Oncology Group WJOG datacenter
scientific contact
Name Haruyasu Murakami
Address Shimonagakubo 1007, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan Japan
Telephone 055-989-5222
Affiliation Shizuoka Cancer Center Thoracic Oncology